About TDSPHARM
TDSPHARM is a company based in Eumseong (South Korea) founded in 2002. The company has 96 employees. TDSPHARM offers products and services including General Medicines, Specialized Medicines, and Medical Supplies. TDSPHARM operates in a competitive market with competitors including Merck, AbbVie, Lilly, Roche and Novo Nordisk, among others.
- Headquarter Eumseong, South Korea
- Employees 96
- Stage Public
- SectorsHealthcare
- Website tdspharm.com
- Legal Name Tdspharm Co., Ltd.
- Annual Revenue$19.12 M (USD)0.37as on Dec 31, 2025
- Net Profit$2.96 M (USD)14.97as on Dec 31, 2025
- EBITDA$3.09 M (USD)1.51as on Dec 31, 2025
- Employee Count96
Associated legal entities of TDSPHARM
TDSPHARM operates through , (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| , CIN U99999MH1977PLC010754 | Active | 10 Aug 1977 | Nanded, Maharashtra | – | – | – | View details |
Products & Services of TDSPHARM
TDSPHARM offers a comprehensive portfolio of products and services, including General Medicines, Specialized Medicines, and Medical Supplies.
Over-the-counter drugs delivered via transdermal patches.
Prescription drugs using innovative transdermal technology.
Non-drug items like patches for various applications.
IPO & Listings of TDSPHARM
TDSPHARM is a publicly listed company on the KRX with ticker symbol 464280 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date21 Aug 2024
- Listed onKRX: 464280
- Listed entityTDSPharm Co., Ltd.
- Exchange sectorHealth technology
- ISINKR7464280007
- Share price5,590.00 KRW (-0.18% on the day) · 2026-10-08
- Market capitalisation29,562,714,062.00 KRW
- Price to earnings5.7
- EPS (diluted, trailing year)974.67 KRW
- Volume (last session)6,617
Financials of TDSPHARM
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 27.62B KRW | 4.27B KRW | 4.46B KRW |
| 2024 | 27.52B KRW | 3.72B KRW | 4.40B KRW |
| 2023 | 30.05B KRW | 4.69B KRW | 6.04B KRW |
| 2022 | 25.59B KRW | 3.46B KRW | 4.96B KRW |
| 2021 | 19.82B KRW | 2.06B KRW | 3.54B KRW |
Balance sheet, profit and loss, cash flow and ratios of , are on its company page.
Detailed financial statements for TDSPHARM
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of TDSPHARM
TDSPHARM operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, AbbVie, Lilly, Roche and Novo Nordisk, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| merck.com | 1891 | Kenilworth, United Kingdom | – | 781 | Pharmaceutical products are manufactured and marketed worldwide. | |
| abbvie.com | 2012 | Chicago, United States | – | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | |
| lilly.com | 1876 | United States | – | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. | |
| roche.com | 1896 | Basel, Switzerland | – | 2,382 | Pharmaceuticals and diagnostics kits are developed for various diseases. | |
| novonordisk.com | 1923 | Bagsvaerd, Denmark | $145,000 | 29,288 | Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured. | |
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| bausch.com | 1853 | Bridgewater, United States | – | 1,681 | Ophthalmic pharmaceuticals and instruments are developed for eye care. | |
| amgen.com | 1980 | Thousand Oaks, United States | – | 26,700 | Developer of pharmaceutical products for treating multiple diseases | |
| sanofi.com | 1973 | Paris, France | – | 1,006,566 | Pharmaceutical and nutraceutical products are developed across seven therapeutic areas. | |
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas |
Detailed competitors of TDSPHARM
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of TDSPHARM
The website of TDSPHARM (tdspharm.com) receives about 3.6K visits a month.
- Monthly visits3.6K
▼ 10.6% vs previous month
Similar companies to TDSPHARM
10 companies that operate in the same segment as TDSPHARM (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about TDSPHARM
TDSPHARM was founded in 2002.
TDSPHARM is headquartered in Eumseong, South Korea. It is registered at Eumseong, Chungcheongbuk-do, South Korea.
TDSPHARM has 96 employees.
Annual revenue of TDSPHARM is $19.12M as on Dec 31, 2025.
TDS Pharm Co., Ltd. was established in 2002 within the pharmaceutical sector. Transdermal drug delivery systems are developed and manufactured to facilitate medication delivery through the skin. These systems address conditions including pain management and skin irritations. Operations focus on production processes tailored to industry standards, with products distributed to meet pharmaceutical needs.
TDSPHARM's top competitors include Merck, Roivant Sciences and Amgen.
TDSPHARM offers General Medicines, Specialized Medicines, and Medical Supplies.
Yes, TDSPHARM is publicly traded on KRX under the ticker symbol 464280.
TDSPHARM operates through ,.